What this trial means for you
This study is active, not recruiting — it is not currently taking new participants, but its results may matter for treatments you're considering. It's studying Tirzepatide, Placebo for type 2 diabetes, obesity.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria * Have a Body Mass Index (BMI) ≥35 kilogram/square meter (kg/m²) at screening. * Have had stable body weight (±5%) during the 90 days preceding screening. * Have been diagnosed with Type 2 Diabetes (T2D). * Have been on a stable treatment of metformin only at least 90 days preceding screening and between screening and randomization with the minimum effective dose of ≥1500 milligram (mg)/day. Exclusion Criteria: * Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D. * Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening. * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema. * Have a prior or planned surgical treatment for obesity. * Use products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening. * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliter/min (mL/min)/1.73 m². * Have any of the following cardiovascular (CV) conditions within 2 months prior to screening. * acute myocardial infarction. * cerebrovascular accident (stroke). * unstable angina . * hospitalization due to congestive heart failure, or * coronary artery revascularization. * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2. * Have a history of chronic or acute pancreatitis.
Study sites by state
Arizona
- Medical Advancement Centers of Arizona — Phoenix
California
- John Muir Physician Network Research Center — Concord
- Care Access - Sacramento — Sacramento
Colorado
- Care Access - Aurora — Aurora
Connecticut
- Chase Medical Research, LLC — Waterbury
Florida
- Retreat Medical Research — Miami
- American Research Centers of Florida — Pembroke Pines
Georgia
- Alta Pharmaceutical Research Center — Norcross
- AGILE Clinical Research Trials, LLC — Sandy Springs
Illinois
- Northwestern University — Chicago
Indiana
- Qualmedica Research, LLC — Evansville
Iowa
- Integrated Clinical Trial Services, Inc. — West Des Moines
North Carolina
- Accellacare - Wilmington - 1917 Tradd Court — Wilmington
Ohio
- Velocity Clinical Research, Mt. Auburn — Cincinnati
Oregon
- Summit Headlands — Portland
Tennessee
- Clinical Research Associates Inc — Nashville
Texas
- Juno Research — Houston
- Southern Endocrinology Associates — Mesquite
Virginia
- Charlottesville Medical Research — Charlottesville
Washington
- Northwest Clinical Research Center — Bellevue
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)